Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN

被引：0

作者：

Zheng, Y. ^{[1
]}

Jin, D. ^{[1
]}

Guan, Y. ^{[1
]}

Ozguroglu, M. ^{[2
]}

Trukhin, D. ^{[3
]}

Poltoratskiy, A. ^{[4
]}

Chen, Y. ^{[5
]}

Havel, L. ^{[6
]}

Hochmair, M. ^{[7
]}

Paz-Ares, L. ^{[8
,9
]}

Jiang, H. ^{[10
]}

Armstrong, J. ^{[11
]}

Chen, C. ^{[1
]}

Liu, Y. H. ^{[10
]}

Roskos, L. ^{[1
]}

机构：

[1] Astrazeneca, San Francisco, CA USA

[2] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey

[3] Odessa Reg Oncol Dispensary, Odessa, Ukraine

[4] Petrov Res Inst Oncol, St Petersburg, Russia

[5] Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA

[6] Charles Univ Prague, Fac Med 1, Thomayer Hosp, Prague, Czech Republic

[7] Krankenhaus Nord, Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria

[8] Univ Complutense, Hosp Univ 12 Octubre, H120 Cnio Lung Canc Unit, Madrid, Spain

[9] Ciberonc, Madrid, Spain

[10] Astrazeneca, Gaithersburg, MD USA

[11] Astrazeneca, Cambridge, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

CASPIAN; population pharmacokinetics; Durvalumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P48.21

引用

页码：S508 / S508

页数：1

共 50 条

[21] Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) plus platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC)
Reinmuth, N.
de Marinis, F.
Leighl, N.
Sadow, S.
Davey, K.
Ozguroglu, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S134 - S134
[22] Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia
Nishio, M.
Ji, J. H.
Hotta, K.
Chiu, C-H.
Lee, J-S.
Azuma, K.
Kim, S-W.
Wu, S-Y.
Dvorkin, M.
Trukhin, D.
Havel, L.
Hochmair, M. J.
Ozguroglu, M.
Bar, J.
Chen, Y.
Goldman, J. W.
Byrne, N.
Laud, P. J.
Shire, N.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2019, 30
[23] Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Goldman, J. W.
Garassino, M. C.
Chen, Y.
Reinmuth, N.
Hotta, K.
Poltoratskiy, A.
Trukhin, D.
Hochmair, M. J.
Ozguroglu, M.
Ji, J. H.
Statsenko, G.
Voitko, O.
Conev, N. V.
Bondarenko, I.
Spencer, S.
Xie, M.
Jones, S.
Franks, A.
Shrestha, Y.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2020, 31 : S1212 - S1213
[24] Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Ji, J. H.
Goldman, J. W.
Garassino, M. C.
Chen, Y.
Reinmuth, N.
Hotta, K.
Poltoratskiy, A.
Trukhin, D.
Hochmair, M. J.
Ozguroglu, M.
Statsenko, G.
Voitko, O.
Conev, N. V.
Bondarenko, I.
Spencer, S.
Xie, M.
Jones, S.
Franks, A.
Shrestha, Y.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2020, 31 : S1388 - S1389
[25] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.
Chen, Yuanbin
Paz-Ares, Luis G.
Dvorkin, Mikhail
Trukhin, Dmytro
Reinmuth, Niels
Chiara Garassino, Marina
Statsenko, Galina
Voitko, Oleksandr
Hochmair, Maximilian
Ozguroglu, Mustafa
Verderame, Francesco
Havel, Libor
Losonczy, Gyorgy
Conev, Nikolay
Hotta, Katsuyuki
Ji, Jun Ho
Broadhurst, Helen
Byrne, Natalie
Thiyagarajah, Piruntha
Wade Goldman, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab ± Tremelimumab plus Chemotherapy in ES-SCLC
Reinmuth, Niels
Paz-Ares, Luis
Chen, Yuanbin
Hotta, Katsuyuki
Trukhin, Dmytro
Statsenko, Galina
Hochmair, Maximilian J.
Ozguroglu, Mustafa
Li, Jun Ho
Voitko, Oleksandr
Poltoratskiy, Artem
Ponce, Santiago
Verderame, Francesco
Havel, Libor
Bondarenko, Igor
Kazarnowiczw, Andrzej
Losonczy, Gyorgy
Conev, Nicolay V.
Armstrong, Jon
Byrne, Natalie
Shire, Norah
Jiang, Haiyi
Goldman, Jonathan
Alt, Juergen
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 115 - 115
[27] Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study.
Ozgurogiu, Mustafa
Goldman, Jonathan W.
Chen, Yuanbin
Garassino, Marina Chiara
Medic, Nenad
Mann, Helen
Chugh, Priti
Dalvi, Tapashi
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study
Reinmuth, N.
Goldman, J. W.
Garassino, M. C.
Chen, Y.
Hotta, K.
Poltoratskiy, A.
Trukhin, D.
Hochmair, M. J.
Ji, J. H.
Ozguroglu, M.
Statsenko, G.
Voitko, O.
Conev, N. V.
Bondarenko, I.
Mann, H.
Xie, M.
Shrestha, Y.
Chugh, P.
Dalvi, T.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2022, 33 : S97 - S98
[29] Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study
Goldman, Jonathan W.
Garassino, Marina Chiara
Chen, Yuanbin
Hotta, Katsuyuki
Poltoratskiy, Artem
Hochmair, Maximilian J.
Ozguroglu, Mustafa
Ji, Jun Ho
Statsenko, Galina
Voitko, Oleksandr
Conev, Nikolay V.
Bondarenko, Igor
Mann, Helen
Xie, Mingchao
Shrestha, Yashaswi
Chugh, Priti
Dalvi, Tapashi
Paz-Ares, Luis
Bischoff, Helge
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 161 - 161
[30] Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in firstline treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Cheng, Y.
Wang, J.
Yao, W.
Yu, Y.
Zang, A.
Cao, L.
Lv, D.
Li, S.
Meng, Z.
Zhang, J.
Guo, Q.
Huang, D.
Liu, A.
Liu, J.
Mao, W.
Tang, K.
Zhang, Y.
Chen, E.
Wang, Z.
Zheng, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1673 - S1673

← 1 2 3 4 5 →